All studies
RecruitingPhase I and Phase II (Integrated)- OtherInterventional

LAPTOP: PHASE 1/2 STUDY IN BORDELINE RESECTABLE, LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER TO ASSESS SAFETY AND POTENTIAL EFFICACY OF DUAL CHECKPOINT INHIBITION IN COMBINATION WITH GEMCITABINE AND NAB-PACLITAXEL FOLLOWED BY IMMUNE-CHEMORADIATION.

Pancreatic cancer can be very difficult to treat, especially when it has spread or is wrapped around important blood vessels. The LAPTOP trial is looking at a new combination of treatments to see if it can help. Participants will receive standard chemotherapy (gemcitabine and nab-paclitaxel) alongside two immunotherapy drugs (nivolumab and ipilimumab). Immunotherapy works by helping your body's own immune system recognise and attack cancer cells. Some patients may also receive radiotherapy combined with these drugs. The main goal of this early-stage trial is to find out if this treatment mix is safe and manageable. Researchers also want to see whether the combination can shrink the cancer. For some people, shrinking the tumour might make it possible to remove it with surgery. The study is open to adults diagnosed with advanced or metastatic pancreatic cancer.

At a glance

Status
Recruiting
Phase
Phase I and Phase II (Integrated)- Other
Sponsor
Region Hovedstaden
Enrolment target
40
Start
08 Oct 2024

What is this study about?

The pancreas is a gland found behind your stomach that helps digest food and control blood sugar. Pancreatic cancer often does not cause symptoms early on, meaning it is frequently diagnosed at an advanced stage. At this point, the tumour may be touching nearby major blood vessels (locally advanced or borderline resectable) or it may have spread to other parts of the body (metastatic). In these situations, surgery to remove the tumour is often not possible right away, or at all.

This clinical trial, called the LAPTOP study, is exploring a new way to tackle advanced pancreatic cancer. Standard treatment usually involves chemotherapy drugs such as gemcitabine and nab-paclitaxel. In this trial, researchers are adding two modern immunotherapy drugs called nivolumab (Opdivo) and ipilimumab (Yervoy). These drugs work by releasing the 'brakes' on your immune system, encouraging your own defence cells to hunt down and fight the cancer. Later in the study, participants may also receive targeted radiotherapy alongside the medicines.

Because this is a Phase 1 and 2 trial, the primary aim is safety. The doctors need to know what side effects occur and what doses people can comfortably handle. They will also carefully measure how well the tumours shrink. If the treatment works well, it could potentially shrink tumours enough for surgeons to safely remove them, or help patients live longer with a better quality of life.

Key takeaways

  • The LAPTOP trial tests a mix of two immunotherapy drugs with standard chemotherapy and radiotherapy.
  • It is aimed at adults with advanced, locally advanced, or metastatic pancreatic cancer.
  • The main focus is finding out if this combination is safe and tolerable.
  • Doctors hope the combination will shrink tumours, potentially making surgery possible for some.
  • Participation is entirely voluntary and you can leave the study at any time.

Who may be eligible?

This trial is for adults aged 18 and over who have been diagnosed with advanced pancreatic cancer. This includes people whose cancer has spread to other organs (metastatic), as well as those whose tumour cannot currently be removed by surgery because it is too close to vital blood vessels (locally advanced or borderline resectable).

To take part, you must be well enough to carry out everyday activities and manage the demands of regular hospital visits. Because the study uses strong treatments, your main organs—such as your heart, liver, and kidneys—need to be working reasonably well.

You may not be eligible if you have certain active autoimmune conditions, serious ongoing infections, or if you have previously had severe reactions to immunotherapy or the chemotherapy drugs used in this study. The trial team will review your full medical history and perform tests to make sure joining is safe for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have been diagnosed with pancreatic cancer that is advanced, metastatic, or borderline resectable.
  3. I am well enough to travel to hospital and manage day-to-day activities.
  4. I do not have a severe autoimmune condition that requires high doses of steroids.
  5. I am willing to attend regular hospital visits for infusions, scans, and blood tests.
Answer every question to see your result.

What does participation involve?

If you join the trial, your care will involve several stages. First, you will have screening tests, such as blood tests, heart checks, and CT scans, to ensure you are fit to take part. During the treatment period, you will visit the hospital clinic regularly to receive your medicines through a drip (infusion) into a vein. You will receive standard chemotherapy together with the immunotherapy drugs, and some participants may also have a planned course of radiotherapy.

Throughout the study, you will have regular blood tests and health checks so doctors can monitor for side effects. You will also have routine scans to see how your tumour is responding. Treatment continues for several months, provided the cancer does not worsen and you do not experience severe side effects. After finishing treatment, the team will continue to check on your health and recovery during regular follow-up appointments.

Potential risks and benefits

Taking part may help shrink your tumour, control the cancer, or potentially make surgery an option, though these benefits cannot be guaranteed. The information gathered may also help improve treatments for people in the future. However, there is a risk of side effects. Chemotherapy can cause tiredness, sickness, hair thinning, and an increased risk of infection. Immunotherapy can cause the immune system to attack normal tissues, leading to inflammation in organs such as the bowels, skin, liver, or lungs. Your medical team will monitor you closely and treat any problems promptly. Joining the study is completely voluntary, and you are free to leave at any time without your normal NHS care being affected.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Denmark

Common questions

What is immunotherapy?

Immunotherapy is a type of cancer treatment that boosts your body's natural defences. Instead of attacking cancer cells directly like chemotherapy, it trains your immune system to recognise and destroy them.

Will taking part guarantee my tumour shrinks?

No clinical trial can guarantee a cure or that your cancer will shrink. The study is being done to find out how well this combination works and whether it is safe.

How are the study drugs given?

All the trial medicines are given through an intravenous drip into a vein, usually at a hospital day unit.

Will I still be able to have standard NHS care?

Yes. If you decide not to join, or if you choose to leave the trial at any stage, you will receive the best standard NHS care available for your condition.

Do I have to pay to take part?

No. Clinical trials in the UK do not charge you for the study drugs or tests. Some trials may also help cover travel expenses to and from hospital visits.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "LAPTOP: PHASE 1/2 STUDY IN BORDELINE RESECTABLE, LOCALLY ADV…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.